Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The original development partner, Janssen Pharmaceuticals, has handed back the license for efinopegdutide to the original developer, Hanmi Pharmaceutical, but the license has been taken up by Merck to be developed as a once weekly treatment for NAFLD
Therapy with the BPC-157 peptide is also part of this treatment
10.3389/fimmu.2025.1615914 26 ChengL.ZhangY.XuQ.LiZ.LiuZ.DaiF
Future studies should expand the sample size, comprehensively collect clinical indicators, identify pathogenic variants, and apply the Mendelian randomization (MR) method to predict causal relationships, with experimental verification as the final step
Its much more than a typical remedy
US$ 26.59
US$ 21.91
US$ 25.17
US$ 22.50
US$ 26.35
